Search results
Gilead gives up on $4.9B antibody as solid tumor plan unravels
FierceBiotech· 2 weeks agoA $4.9 billion hole has appeared in Gilead Sciences' pipeline. After years of setbacks, the Big Biotech dealt a final blow to its anti-CD47 monoclonal & ...
Drug appears to reverse type 1 diabetes in mice
Futurity· 1 week agoAn experimental monoclonal antibody drug appears to prevent and reverse the onset of clinical type 1 diabetes in mice, and in some cases, to lengthen the ...
Antigenic Characterization of Novel Human Norovirus GII.4 Variants San Francisco 2017 and Hong Kong...
Centers for Disease Control and Prevention· 2 weeks agoNovel Human Norovirus GII.4 Variants
Cytokine Release Syndrome: What to Know
Verywell Health via Yahoo News· 5 days agoCytokine release syndrome (CRS) occurs when the immune system responds to infection or immunotherapy drugs more aggressively than it should. Learn more...
Taking the bite out of snake venom
Phys.org· 1 week agoEvery year around 5.4 million people globally—often in the world's poorest communities—are bitten by venomous snakes, with countries such as Bangladesh,...
Sanofi crosses Sjögren's off $5B drug's hit list after phase 2 data disappoint
FierceBiotech· 2 weeks agoSanofi is narrowing development of one of its 5 billion euro ($5.4 billion), “pipeline-in-a-product”...
HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update
NBC 10 - FOX 14 Monroe· 1 week agoDelivered solid performance to start 2024, with record-breaking first quarter revenue of 34.1 billion KRW. Phase 3 VELOS-4 study of tanfanercept in dry eye disease expected ...
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 weeks agoZoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 6 days agoNew York, USA, May 02, 2024 (GLOBE NEWSWIRE) -- Inflammatory Bowel Disease Market To Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies Developing Therapies - Arena Pharmaceuticals, Pfizer, Abivax, Janssen, Celgene, Eli
Realising the potential of correlates of protection for vaccine development, licensure and use:...
Nature· 1 week agoVaccine development, particularly late-stage development is costly, time-consuming and is associated with high risk of candidate failure, with as few as 10% of vaccine candidates achieving licensure ...
